Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|412-420

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 412-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of addition of statins to antiviral therapy in hepatitis C virus–infected persons: Results from ERCHIVES

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 365-374

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1b

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 3-4

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct‐acting antiviral therapy for chronic hepatitis C: Data from a national US cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 187-197

John Wiley & Sons Inc

Access to resources Recommend Favorite

Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 791-793

John Wiley & Sons Inc

Access to resources Recommend Favorite